open-burger-menu
Search Icon
Or Choose Category
End of Life
Life & the Law
Maternal & Public Health
Abortion
Fetal Tissue, Stem Cells & Bioethics
Fetal Development
Abortion Drugs
Trending Research
📈 NEW Report: Abortions, Tax Funding UP at Planned Parenthood >>
Search Icon
Or Choose Category
End of Life
Life & the Law
Maternal & Public Health
Abortion
Fetal Tissue, Stem Cells & Bioethics
Fetal Development
Abortion Drugs
Trending Research
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

close-panel
Or Choose Category
End of Life
Life & the Law
Maternal & Public Health
Abortion
Fetal Tissue, Stem Cells & Bioethics
Fetal Development
Abortion Drugs
Trending Research

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Research Type:

Or Choose Category
End of Life
Life & the Law
Maternal & Public Health
Abortion
Fetal Tissue, Stem Cells & Bioethics
Fetal Development
Abortion Drugs
Trending Research

Sort 1464 results by:

Filter results further
Filter Applied. Clear All

Latest Posts

October 6, 2026 A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Inside The Government Decision That Opened Up Abortion Pill Floodgates Inside The Government Decision That Opened Up Abortion Pill Floodgates October 6, 2026 Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone
Research Type
Publication Type
By State
See All
By Author
See All
Reset All Filters

Did You Know ?

Did You Know ?

In the fourth week, the embryonic heart starts beating. The neural tube, which becomes the brain and spinal cord, forms. At this point, a woman has likely only been aware of her pregnancy for one week.

Did You Know ?

In the seventh week after conception, networks of neurons produce brain waves that have been recorded as early as 6 ½ weeks after conception. The embryo spontaneously moves his arms, hands, and legs, and may even hiccup. The embryo’s heart now has all four chambers.

Did You Know ?

By the seventeenth and eighteenth week after gestation, the fetus shows a clear response to pain in multiple studies, and at least one brain pathway is mature enough to create a perception of pain. The fetus also practices breathing, crying, and breastfeeding in the womb. The fetal heart has beat over 20 million times and circulates about 55 quarts of blood per day.

Did You Know ?

In the eighth month of pregnancy the fetal brain is ready to learn! At 32 weeks after conception, neurons are creating 40,000 new connections, called synapses, every second! With repeated exposures, the fetus can learn flavors, nursery rhymes, songs, and even words that she will recognize after birth!

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review
Latest Research / Life & the Law

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review

This paper critically analyzes the FDA's 2021 REMS Review leading to the removal of the in-person dispensing requirement for mifepristone.

Zachary Sluzala,… Ingrid Skop,…
October 6, 2026
Inside The Government Decision That Opened Up Abortion Pill Floodgates
Latest Research / Abortion Drugs

Inside The Government Decision That Opened Up Abortion Pill Floodgates

The decision "fell well short" of the FDA's standards.

charlotte-lozier-institute Charlotte Lozier Institute
October 6, 2026
Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone
Latest Research / Life & the Law

Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

This paper critically analyzes the FDA's 2021 literature review that served as the basis for its controversial decision to remove…

Ingrid Skop,…
October 6, 2026
Peer-Reviewed Article: FDA Lacked Evidence to Drop In-Person Abortion Drug Requirement
Latest Research / General

Peer-Reviewed Article: FDA Lacked Evidence to Drop In-Person Abortion Drug Requirement

A new peer-reviewed article on the Food and Drug Administration’s (FDA) 2021 complete review of mifepristone’s Risk Evaluation and Mitigation…

charlotte-lozier-institute Charlotte Lozier Institute
October 6, 2026
Abortion Reporting: Kentucky (2025)
Latest Research / Abortion

Abortion Reporting: Kentucky (2025)

In 2025, five brick-and-mortar abortions were reported in Kentucky by the state’s Cabinet for Health and Family Services. The data…

Elyse Gaitan Mia Steupert,…
October 5, 2026
Abortion Reporting: Minnesota (2019)
Maternal & Public Health

Abortion Reporting: Minnesota (2019)

Minnesota’s annual abortion report for 2019 was published online by the Minnesota Department of Health in July 2020. The report shows that Minnesota’s abortion total changed very little from the year before.

Tessa Cox
October 16, 2020
Abortion Cases in the Higher Federal Courts
Life & the Law

Abortion Cases in the Higher Federal Courts

Abortion advocates contend that the United States Supreme Court is on the precipice of reversing Roe v. Wade—the conservative justices are simply waiting for the arrival of another like-minded colleague, and they may find that person in Judge Amy Coney Barrett. An honest review of recent decisions by the Court, however, simply fails to support this belief. Instead of building a case for Roe’s demise, the Court has managed to make abortion jurisprudence even murkier for legislators and lower courts trying to determine the constitutionality of abortion laws, while otherwise refusing to make substantive decisions in abortion cases.

Mary E. Harned,…
October 12, 2020
COVID-19, Nursing Homes, and the Need to Protect the Elderly
Maternal & Public Health

COVID-19, Nursing Homes, and the Need to Protect the Elderly

In early 2020 news began circulating that a life-threatening respiratory illness was sweeping across the world and had made its way to the United States. Reactions to the severity of the problem varied, but most jurisdictions seemed underprepared to deal with how COVID-19 would impact long-term care facilities, specifically nursing homes.

Hannah Howard
October 7, 2020
CLI Responds to Misinformation Regarding President Trump’s COVID-19 Treatment
Maternal & Public Health

CLI Responds to Misinformation Regarding President Trump’s COVID-19 Treatment

“Uninformed commentary has emerged this morning stating that President Trump has received a medication created with the use of human embryonic stem cells.  CLI has reviewed the published information and our conclusion is straightforward: The president was not given any medicines to treat COVID-19 that involved the destruction of human life.  No human embryonic stem cells or human fetal tissue were used to produce the treatments President Trump received--period.

David Prentice, Ph.D. Tara Sander Lee,…
October 6, 2020
Federal Bioethics Commissions and Bias Against the Unborn
Fetal Tissue, Stem Cells & Bioethics

Federal Bioethics Commissions and Bias Against the Unborn

In August, the Trump administration’s new Human Fetal Tissue Research Ethics Advisory Board reviewed requests made to the National Institutes of Health (NIH) for federally funded fetal tissue research. The Board recommended denying most of these requests.

Richard Doerflinger, M.A.
October 5, 2020
Maternal & Public Health

Medical and Social Risks Associated with Unmitigated Distribution of Mifepristone: A Primer

Chemical abortions, or “medication” abortions, have become a more prevalent method of abortion in recent years in the United States. In 2000, the Food and Drug Administration (FDA) approved the use of mifepristone, in conjunction with the drug misoprostol, as an abortion-inducing, two-drug process. By 2018, the Charlotte Lozier Institute estimates that 41% of U.S. abortions were chemically induced.

Hannah Howard
October 1, 2020
Update: COVID-19 Vaccine Candidates and Abortion-Derived Cell Lines
Fetal Tissue, Stem Cells & Bioethics

Update: COVID-19 Vaccine Candidates and Abortion-Derived Cell Lines

Accurate information about the development and production of COVID-19 vaccines is essential, especially because many proposed candidates use newer molecular technologies for production of a viral vaccine.  One concern regarding the ethical assessment of viral vaccine candidates is the potential use of abortion-derived cell lines in the development, production or testing of a vaccine.  This analysis utilizes data from the primary scientific literature when available, along with data from clinical trial documents, reputable vaccine tracking websites, and published commercial information.1  It is the hope that by providing accurate data, recipients can make well-informed decisions regarding vaccine choices.

David Prentice, Ph.D.
September 30, 2020
Maternal & Public Health

Abortion Reporting: South Dakota (2019)

South Dakota’s provisional 2019 abortion report was published by the South Dakota Department of Health in June 2020, and the final report was released in September. The final report shows that chemical abortions in South Dakota remain low.

Tessa Cox
September 29, 2020

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image